Archive for the ‘life extension’ category: Page 491

Apr 5, 2017

Dr. João Pedro de Magalhães – A life dedicated to conquering aging

Posted by in category: life extension

Another exclusive interview with a hero of gerontology.

Dr. Joao Pedro de Magalhaes talks about aging research in this exclusive interview with LEAF.

Read more

Apr 4, 2017

Investment Strategist Jim Mellon Considers the Near Future of Longevity Science

Posted by in categories: biotech/medical, computing, life extension, science

Interest in rejuvenation biotechnology is growing in the investment quarter.

Mainstream interest in rejuvenation biotechnology is growing.

“Investment in the development of rejuvenation therapies represents an enormous opportunity for profit; these are products for which every adult human being much over the age of 30 is a potential customer at some price point. That is larger than near every existing industry, either within or outside the field of medicine, even given that customers will only purchase such a therapy once every few years, for clearance of metabolic waste, or even just once, for treatments like the SENS approach of allotopic expression of mitochondrial genes. Among the first successful companies in this space, some will grow to become among the largest in the world: I’d wager that the Ford or Microsoft of rejuvenation will be a lot larger than the actual Ford of automobiles or Microsoft of personal computing.”

Continue reading “Investment Strategist Jim Mellon Considers the Near Future of Longevity Science” »

Apr 3, 2017

Is Zoltan Istvan a Libertarian?

Posted by in categories: biotech/medical, evolution, geopolitics, life extension, transhumanism

This is a fair enough article, though I believe I’m more Libertarian than it paints me. I think a lot of people forget or simply don’t know my book The Transhumanist Wager (how I started my futurist career back in 2009) is known by many as transhumanist libertarian manifesto. Also, ideas from my past political campaign do not always correspond to my current gubernatorial run:

Like many libertarians, I was initially excited when Zoltan Istvan announced his candidacy for Governor of California.

Istvan is the founder of the Transhumanist Party and author of “The Transhumanist Wager,” which is considered a manifesto on transhumanist philosophy. The basic premise of transhumanism is that the next step in human evolution will be to improve our bodies and expand our lifespan with radical technology, eventually leading towards immortality. While he still needs to obtain the nomination, having someone announce their intents this early gave me hope that maybe the party would have a shot at making an impact in the California mid-terms.

Continue reading “Is Zoltan Istvan a Libertarian?” »

Apr 3, 2017

Rejuvenation would be only for the rich

Posted by in categories: biotech/medical, life extension

A rebuttal of the ‘only for the rich’ objection often raised against the development of rejuvenation biotechnologies.

Some people are worried that rejuvenation might be a privilege accorded only to the rich. It’s okay to be concerned that this might happen, because if enough people are concerned about it, it’s more likely that we will actually do what it takes prevent this from happening. However, some people aren’t just concerned about it; they are argue that, to forestall the risk that rejuvenation may be something only few can afford, it should be never developed in the first place. This is an extremely flawed line of reasoning, for several reasons.

Read more

Apr 3, 2017

Google’s co-founders and other Silicon Valley billionaires are trying to live forever

Posted by in category: life extension

Live enough to live for ever…

The super rich are investing in new ways to make death optional.

Read more

Apr 2, 2017

This scientific breakthrough could reverse the aging process

Posted by in categories: biotech/medical, life extension, space

The fountain of youth isn’t so far off.

Scientists have discovered a revolutionary molecule that could be crucial to the health and survival of Mars astronauts – and crucial to helping us look young forever.

Our cells have the ability to repair themselves, but that declines with age – and scientists finally discovered why. The breakthrough comes after six years of DNA research from scientists at Harvard Medical School and University of New South Wales. Their findings were published Friday in Science.

Continue reading “This scientific breakthrough could reverse the aging process” »

Apr 2, 2017

Artificial intelligence enters the nutraceutical industry

Posted by in categories: biotech/medical, information science, life extension, robotics/AI

Wednesday, March 1st Baltimore, MD — In March 2016 Insilico Medicine initiated a research collaboration with Life Extension to apply advanced bioinformatic methods and deep learning algorithms to screen for naturally occurring compounds that may slow down or even reverse the cellular and molecular mechanisms of aging. Today Life Extension (LE) launched a new line of nutraceuticals called GEROPROTECTTM, and the first product in the series called Ageless CellTM combines some of the natural compounds that were shortlisted by Insilico Medicine’s algorithms and are generally recognized as safe (GRAS).

The first research results on human biomarkers of aging and the product will be presented at the Re-Work Deep Learning in Healthcare Summit in London 28.02−01.03, 2017, one of the popular multidisciplinary conferences focusing on the emerging area of deep learning and machine intelligence.

“We salute Life Extension on the launch of GEROPROTECTTM: Ageless Cell, the first combination of nutraceuticals developed using our artificial intelligence algorithms. We share the common passion for extending human productive longevity and investing every quantum of our energy and resources to identify novel ways to prevent age-related decline and diseases. Partnering with Life Extension has multiple advantages. LE has spent the past 37 years educating consumers on the latest in nutritional therapies for optimal health and anti-aging and is an industry leader and a premium brand in the supplement industry. Also, LE also has a unique mail order blood test service that allows US customers to perform comprehensive blood tests to help identify potential health concerns and to track the effects of the nutraceutical products,” said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.

Continue reading “Artificial intelligence enters the nutraceutical industry” »

Apr 2, 2017

A comprehensive new article on #transhumanism and my work by Prof. Steve Fuller is out in Issues, one of the major magazines of the National Academy of Sciences

Posted by in categories: geopolitics, life extension, transhumanism

It’s now out in print. It’s great to see my past presidential campaign for the Transhumanist Party getting this type of formal recognition. The Transhumanist Bill of Rights, the Transhumanist Wager concept, Libertarian Party presidential nominee Gary Johnson considering me as a running mate, Immortality Bus, and my #libertarianism are all mentioned. http://www.academia.edu/32185481/Does_this_pro-science_party_deserve_our_votes

Read more

Mar 31, 2017

Reversing Ageing

Posted by in categories: biotech/medical, life extension

A new powerful drug reverses ageing in mice.

Read more

Mar 31, 2017

How to avoid the adverse reactions of senolytics through better design

Posted by in categories: biotech/medical, life extension

Another biomarker of senescent cells could be p16, a protein whose levels increase when cells stop dividing if old and also a protein whose gene is turned off in many human cancers.

Coming back to our topic – designing senolytics that avoid the apoptosis of young, healthy cells – the ideal senolytic should accomplish two things: –turn on p53 at increased levels to determine stubborn, senescent cells to commit suicide –do that on senescent cells only.

And in order to accomplish the second part, such a drug should be ‘programmed’ to only act on those cells where it recognizes senescence-associated biomarkers. There is no single biomarker today that stains positive or negative on all types of senescence cells, but increased levels of beta-galactosidase and p16 proteins could be a welcome start to identify old cells in vivo when designing such a drug.

Continue reading “How to avoid the adverse reactions of senolytics through better design” »